从药师角度分析某院肿瘤内科DRG病组亏损的影响因素及应对策略:以RE16病组为例  

Influencing Factors and Coping Strategies of Loss in DRG Disease Group in the Department of Oncology in a Hospital from the Pharmacists′Point of View:Taking RE16 Disease Group as an Example

作　　者：许瑞[1] 康万里[1] 郭逸宁 郑梅琴[1] 郭振勇[1] 徐建[1] 刘硕[1] XU Rui;KANG Wanli;GUO Yining;ZHENG Meiqin;GUO Zhenyong;XU Jian;LIU Shuo(Beijing Chest Hospital,Capital Medical University,Beijing,China 101149;School of Journalism and Communication,Beijing Normal University·Center for Computational Communication Research,Beijing Normal University,Zhuhai,Guangdong,China 519087)

机构地区：[1]首都医科大学附属北京胸科医院,北京101149 [2]北京师范大学新闻传播学院·北京师范大学计算传播学研究中心,广东珠海519087

出　　处：《中国药业》2024年第21期14-17,共4页China Pharmaceuticals

摘　　要：目的减少医院肿瘤内科疾病诊断相关分组(DRG)RE16病组的亏损。方法检索医院DRG分析系统出院结算日期为2022年3月15日至2023年4月30日的1179例次肿瘤内科患者的DRG数据,按DRG盈利与亏损分为盈利组(824例次)和亏损组(355例次),比较两组患者的性别、年龄、住院天数、药费、药占比、材料费、材料费占比、检查费、检查费占比、化验费、化验费占比、治疗费、治疗费占比,分析亏损的影响因素,并从药师角度分析可能对RE16病组亏损有显著影响的药品。结果亏损组和盈利组的住院天数、药费、材料费、材料费占比、检查费、检查费占比、化验费、化验费占比、治疗费、治疗费占比均有显著差异(P<0.05)。药费在RE16病组的占比最高(75.60%),其次为化验费(13.08%)和材料费(4.04%)。亏损组聚乙二醇化重组人粒细胞刺激因子(长效)、因卡膦酸二钠及其他辅助用药如肌苷注射液、参麦注射液、斑蝥维生素B6注射液、金复康口服液的使用率均显著高于盈利组(51.27%比27.66%,19.15%比5.83%,21.41%比7.16%,12.68%比4.85%,8.45%比2.91%,2.54%比1.33%,P<0.05)。结论药费对RE16病组亏损有影响,可通过开展重点药物专项点评和实行药品分级管理减少RE16病组的亏损。Objective To reduce the loss of the disease diagnosis-related group(DRG) RE16 disease group in the Oncology Department of a hospital.Methods The DRG data of 1 179 patients with discharge settlement dates from March 15,2022 to April30,2023 in the Department of Oncology were retrieved from the DRG Analysis System of the hospital.The patients were divided into the profit group(824 cases) and the loss group(355 cases) based on DRG profit and loss.The gender,age,length of hospital stay,drug cost,drug proportion,material fee,proportion of material fee,examination fee,proportion of examination fee,laboratory test fee,proportion of laboratory test fee,treatment fee and proportion of treatment fee in the two groups were compared.The influencing factors of the loss were analyzed,and drugs that might have a significant effect on the loss of the RE16 disease group were analyzed from the pharmacists′ point of view.Results There were significant differences in the length of hospital stay,drug cost,material fee,proportion of material fee,examination fee,proportion of examination fee,laboratory test fee,proportion of laboratory test fee,treatment fee,and proportion of treatment fee between the loss group and the profit group(P < 0.05).The proportion of drug cost was the highest in the RE16 disease group(75.60%),followed by the laboratory test fee(13.08%) and the material fee(4.04%).The application rates of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor(long-acting),bisphosphonates,and other adjunctive drugs in the loss group were significantly higher than those in the profit group(51.27% vs.27.66%,19.15% vs.5.83%,21.41% vs.7.16%,12.68% vs.4.85%,8.45% vs.2.91%,2.54% vs.1.33%,P < 0.05).Conclusion Drug costs have an effect on the loss of the RE16 disease group,which can be reduced by conducting special reviews of key drugs and implementing drug classification management.

关 键 词：疾病诊断相关分组 肿瘤内科 亏损 药房管理 

分 类 号：R95[医药卫生—药学]